A phase 2 study of irinotecan and cetuximab on an every 2 week schedule, as second line therapy in patients with advanced colorectal cancer.

Trial Profile

A phase 2 study of irinotecan and cetuximab on an every 2 week schedule, as second line therapy in patients with advanced colorectal cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Jul 2016

At a glance

  • Drugs Cetuximab (Primary) ; Irinotecan (Primary)
  • Indications Colorectal cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 May 2011 Planned End Date changed from 1 Jul 2009 to 1 Jul 2011 as reported by ClinicalTrials.gov.
    • 03 Oct 2008 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top